Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer
An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib t...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2021/02/01, Vol.60(3), pp.441-444 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 444 |
|---|---|
| container_issue | 3 |
| container_start_page | 441 |
| container_title | Internal Medicine |
| container_volume | 60 |
| creator | Oyama, Baku Morikawa, Kei Sakaguchi, Tadashi Tsunoda, Akihito Kida, Hirotaka Inoue, Takeo Mineshita, Masamichi |
| description | An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed. |
| doi_str_mv | 10.2169/internalmedicine.4237-19 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7925278</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486180059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-41d0f3981898d080a7ddd585f6dc7542d3b0c5d00021998400ad8ef2f5c7b1593</originalsourceid><addsrcrecordid>eNplkV9v2yAUxdG0ac26fYUKqc_uLmBseKlUZekfLdqqrXtGBHBClOAUcCd_-9lLGnXdy-WBc8-5-h2EMIELSir52YfsYtCbrbPe-OAuSsrqgsg3aEJYKYuaMv4WTUASUdBhnKAPKa0BmKglfY9OGONEVIRO0P2X2C0LH2xnnMW3_c7F5ELy2T_53OOffbCx3Tq86PHs5vpH8fD1DvuANb7X2buQ8W-fV3jehSWe6mBc_IjeNXqT3KfDe4p-Xc8eprfF_PvN3fRqXpgKZC5KYqFhUhAhhQUBurbWcsGbypqal9SyBRhuAYASKUUJoK1wDW24qReES3aKLve-u24xYDDDLVFv1C76rY69arVX__4Ev1LL9kkNBDitxWBwfjCI7WPnUlbrthuhJkXLAY4A-Bsj9ioT25Sia44JBNTYhXrdhRq7UGRcPXt54XHxGf4g-LYXrFPWS3cU6Ji92bj_nStQbByHhKPQrHRULrA_H4mnsA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486180059</pqid></control><display><type>article</type><title>Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><creator>Oyama, Baku ; Morikawa, Kei ; Sakaguchi, Tadashi ; Tsunoda, Akihito ; Kida, Hirotaka ; Inoue, Takeo ; Mineshita, Masamichi</creator><creatorcontrib>Oyama, Baku ; Morikawa, Kei ; Sakaguchi, Tadashi ; Tsunoda, Akihito ; Kida, Hirotaka ; Inoue, Takeo ; Mineshita, Masamichi</creatorcontrib><description>An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.4237-19</identifier><identifier>PMID: 33518612</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adenocarcinoma ; Adenocarcinoma of Lung - drug therapy ; afatinib ; Afatinib - adverse effects ; Aged, 80 and over ; Blood tests ; Case Report ; Diarrhea ; drug-induced hypersensitivity syndrome ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB Receptors - genetics ; Erythema ; Female ; HHV-6 ; Humans ; Hypersensitivity ; Inflammation ; Internal medicine ; Lung cancer ; Lung Neoplasms - drug therapy ; Mutation ; Pharmaceutical Preparations ; Prednisolone</subject><ispartof>Internal Medicine, 2021/02/01, Vol.60(3), pp.441-444</ispartof><rights>2021 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2021</rights><rights>Copyright © 2021 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-41d0f3981898d080a7ddd585f6dc7542d3b0c5d00021998400ad8ef2f5c7b1593</citedby><cites>FETCH-LOGICAL-c609t-41d0f3981898d080a7ddd585f6dc7542d3b0c5d00021998400ad8ef2f5c7b1593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925278/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925278/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33518612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oyama, Baku</creatorcontrib><creatorcontrib>Morikawa, Kei</creatorcontrib><creatorcontrib>Sakaguchi, Tadashi</creatorcontrib><creatorcontrib>Tsunoda, Akihito</creatorcontrib><creatorcontrib>Kida, Hirotaka</creatorcontrib><creatorcontrib>Inoue, Takeo</creatorcontrib><creatorcontrib>Mineshita, Masamichi</creatorcontrib><title>Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma of Lung - drug therapy</subject><subject>afatinib</subject><subject>Afatinib - adverse effects</subject><subject>Aged, 80 and over</subject><subject>Blood tests</subject><subject>Case Report</subject><subject>Diarrhea</subject><subject>drug-induced hypersensitivity syndrome</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - genetics</subject><subject>Erythema</subject><subject>Female</subject><subject>HHV-6</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Inflammation</subject><subject>Internal medicine</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Mutation</subject><subject>Pharmaceutical Preparations</subject><subject>Prednisolone</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkV9v2yAUxdG0ac26fYUKqc_uLmBseKlUZekfLdqqrXtGBHBClOAUcCd_-9lLGnXdy-WBc8-5-h2EMIELSir52YfsYtCbrbPe-OAuSsrqgsg3aEJYKYuaMv4WTUASUdBhnKAPKa0BmKglfY9OGONEVIRO0P2X2C0LH2xnnMW3_c7F5ELy2T_53OOffbCx3Tq86PHs5vpH8fD1DvuANb7X2buQ8W-fV3jehSWe6mBc_IjeNXqT3KfDe4p-Xc8eprfF_PvN3fRqXpgKZC5KYqFhUhAhhQUBurbWcsGbypqal9SyBRhuAYASKUUJoK1wDW24qReES3aKLve-u24xYDDDLVFv1C76rY69arVX__4Ev1LL9kkNBDitxWBwfjCI7WPnUlbrthuhJkXLAY4A-Bsj9ioT25Sia44JBNTYhXrdhRq7UGRcPXt54XHxGf4g-LYXrFPWS3cU6Ji92bj_nStQbByHhKPQrHRULrA_H4mnsA</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Oyama, Baku</creator><creator>Morikawa, Kei</creator><creator>Sakaguchi, Tadashi</creator><creator>Tsunoda, Akihito</creator><creator>Kida, Hirotaka</creator><creator>Inoue, Takeo</creator><creator>Mineshita, Masamichi</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20210201</creationdate><title>Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer</title><author>Oyama, Baku ; Morikawa, Kei ; Sakaguchi, Tadashi ; Tsunoda, Akihito ; Kida, Hirotaka ; Inoue, Takeo ; Mineshita, Masamichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-41d0f3981898d080a7ddd585f6dc7542d3b0c5d00021998400ad8ef2f5c7b1593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma of Lung - drug therapy</topic><topic>afatinib</topic><topic>Afatinib - adverse effects</topic><topic>Aged, 80 and over</topic><topic>Blood tests</topic><topic>Case Report</topic><topic>Diarrhea</topic><topic>drug-induced hypersensitivity syndrome</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - genetics</topic><topic>Erythema</topic><topic>Female</topic><topic>HHV-6</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Inflammation</topic><topic>Internal medicine</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Mutation</topic><topic>Pharmaceutical Preparations</topic><topic>Prednisolone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oyama, Baku</creatorcontrib><creatorcontrib>Morikawa, Kei</creatorcontrib><creatorcontrib>Sakaguchi, Tadashi</creatorcontrib><creatorcontrib>Tsunoda, Akihito</creatorcontrib><creatorcontrib>Kida, Hirotaka</creatorcontrib><creatorcontrib>Inoue, Takeo</creatorcontrib><creatorcontrib>Mineshita, Masamichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oyama, Baku</au><au>Morikawa, Kei</au><au>Sakaguchi, Tadashi</au><au>Tsunoda, Akihito</au><au>Kida, Hirotaka</au><au>Inoue, Takeo</au><au>Mineshita, Masamichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>60</volume><issue>3</issue><spage>441</spage><epage>444</epage><pages>441-444</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>33518612</pmid><doi>10.2169/internalmedicine.4237-19</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2021/02/01, Vol.60(3), pp.441-444 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7925278 |
| source | MEDLINE; PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central |
| subjects | Adenocarcinoma Adenocarcinoma of Lung - drug therapy afatinib Afatinib - adverse effects Aged, 80 and over Blood tests Case Report Diarrhea drug-induced hypersensitivity syndrome Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics Erythema Female HHV-6 Humans Hypersensitivity Inflammation Internal medicine Lung cancer Lung Neoplasms - drug therapy Mutation Pharmaceutical Preparations Prednisolone |
| title | Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A07%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug-induced%20Hypersensitivity%20Syndrome%20by%20EGFR-TKI%20in%20a%20Patient%20with%20Lung%20Cancer&rft.jtitle=Internal%20Medicine&rft.au=Oyama,%20Baku&rft.date=2021-02-01&rft.volume=60&rft.issue=3&rft.spage=441&rft.epage=444&rft.pages=441-444&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.4237-19&rft_dat=%3Cproquest_pubme%3E2486180059%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486180059&rft_id=info:pmid/33518612&rfr_iscdi=true |